Jun. 26th, 2017. (BUSINESS WIRE) – Cerveau Technologies Inc. today announced a research collaboration with the NYU Langone Medical Center to support various research projects studying the stages of Alzheimer’s Disease and other Neurodegenerative diseases. These research projects will utilize an investigational imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for […]
Jun. 16th, 2017, (BUSINESS WIRE) – Cerveau Technologies, Inc. has announced that the United States Food and Drug Administration has cleared their IND for [18F]MK-6240, an investigational tau imaging agent. Cerveau plans to work with partners to study the use of this product in Positron Emission Tomography (PET) scans for assessing the status and progression of […]
May. 24th, 2017. (BUSINESS WIRE) – Cerveau Technologies, Inc. today announced a research collaboration with the Clinical Imaging Research Centre (CIRC), a joint venture by the Agency for Science, Technology and Research (A*STAR) and the National University of Singapore (NUS), to support various research projects studying the stages of Alzheimer’s Disease and other Neurodegenerative disease. […]
Mar. 3rd, 2017. (BUSINESS WIRE) – Cerveau Technologies, Inc. today announced a clinical research agreement with the University of Wisconsin-Madison Alzheimer’s Disease Research Center to support various research projects studying the stages of Alzheimer’s Disease and other neurodegenerative diseases. These research projects will utilize an early stage imaging agent (MK-6240) to be used in Positron Emission […]
Cerveau Technologies, Inc. today announced finalization of an exclusive license agreement with Merck, known as MSD outside the US and Canada, for the global development and commercialization of Merck’s early stage investigational imaging agent (MK-6240) being evaluated for use in Positron Emission Tomography (PET) scans to image neurofibrillary tangles (NFTs) in the brain. NFTs made […]
Sept. 28th, 2016. Mr. Xu Xinsheng and Mr. Chu Wei, the President and COO of Sinotau Pharmaceuticals Group, had a highly fruitful meeting with Professor Serge Gauthier, McGill University (Canada), Mr. Rick Hiatt, CEO of the Canadian company Enigma, and a selected group of Chinese Pharma experts. Alzheimer’s disease was the main issue discussed during […]